Resumen de acción TEVA
Teva Pharmaceutical Industries Limited desarrolla, fabrica, comercializa y distribuye medicamentos genéricos, medicamentos especializados y productos biofarmacéuticos en Norteamérica, Europa, Israel y a escala internacional.
| Puntuación del snowflake | |
|---|---|
| Valoración | 6/6 |
| Crecimiento futuro | 4/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 2/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en TEVA a partir de nuestros controles de riesgos.
Competidores de Teva Pharmaceutical Industries Limited
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$17.43 |
| Máximo en las últimas 52 semanas | US$19.31 |
| Mínimo de 52 semanas | US$8.55 |
| Beta | 0.88 |
| 1Cambio en 1 mes | 0.87% |
| Variación en 3 meses | 1.57% |
| Cambio de 1 año | 90.49% |
| 3Variación en 3 años | 85.43% |
| Variación en 5 años | 78.22% |
| Variación desde la OPV | 4,190.46% |
Noticias y actualizaciones recientes
Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt
Oct 23Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?
Oct 21
Cheap Teva Stock Should Reward Patient Investors
Sep 09Recent updates
Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt
Oct 23Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?
Oct 21Cheap Teva Stock Should Reward Patient Investors
Sep 09Teva's Transformation: From Generics Leader To Branded Drug Innovator
Aug 14Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 02Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs
Jul 26Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Jul 12Teva Pharmaceutical: Buy This Bargain Before It's Gone
Jun 07Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
May 14Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)
May 09Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Mar 26Teva Pharmaceutical Industries: Potential Outweighs Concerns
Mar 25Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
Feb 26A Review Of Teva's Prospects
Feb 15Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry
Jan 07These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way
Dec 11Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)
Dec 08Teva: Deeply Undervalued FCF Machine
Nov 20Teva: Focus On Innovation And Growth Means The Times They Are A Changing
Sep 14Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt
Sep 09The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
Aug 26Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain
Aug 02Teva Pharmaceutical: Lacking Capabilities For Strategic Investments
Jul 20Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence
Jun 15Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load
Jun 06Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Feb 20What To Expect From Teva Pharmaceutical In 2023 With A New CEO
Feb 15Can Teva Pharmaceutical's Q4 results bring positive surprise?
Feb 07Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment
Jan 19Tamiflu supplies released from national stockpile as nationwide shortage persists
Jan 12Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year
Dec 28Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex
Dec 16Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit
Nov 10Teva Pharmaceutical to pay New York $523M as part of opioid settlement
Nov 03Teva data indicates long-term benefit of Austedo for chorea associated with Huntington's
Oct 18Rentabilidad de los accionistas
| TEVA | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | -6.2% | -4.5% | 2.3% |
| 1Y | 90.5% | 10.9% | 35.1% |
Rentabilidad vs. Industria: TEVA superó a la industria US Pharmaceuticals, que obtuvo un rendimiento del 10.9% el año pasado.
Rentabilidad vs. Mercado: TEVA superó al mercado US, que obtuvo un rendimiento del 35.1% el año pasado.
Volatilidad de los precios
| TEVA volatility | |
|---|---|
| TEVA Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 2.9% |
Precio estable de las acciones: TEVA no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de TEVA (4%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1901 | 35,737 | Richard Francis | www.tevapharm.com |
Teva Pharmaceutical Industries Limited desarrolla, fabrica, comercializa y distribuye medicamentos genéricos, medicamentos especializados y productos biofarmacéuticos en Norteamérica, Europa, Israel y a escala internacional. Ofrece medicamentos genéricos en diversas formas farmacéuticas, como comprimidos, cápsulas, inyectables, inhalantes, líquidos, parches transdérmicos, pomadas y cremas; productos estériles, hormonas, medicamentos de alta potencia y sustancias citotóxicas en formas farmacéuticas parenterales y sólidas; y productos genéricos con dispositivos médicos y productos combinados. La empresa se centra en las áreas del sistema nervioso central (SNC), respiratorio y oncología.
Resumen de fundamentos de Teva Pharmaceutical Industries Limited
| Estadísticas fundamentales de TEVA | |
|---|---|
| Capitalización bursátil | US$21.27b |
| Beneficios(TTM) | -US$453.00m |
| Ingresos (TTM) | US$16.29b |
1.2x
Ratio precio-ventas (PS)-43.6x
Ratio precio-beneficio (PE)¿Está TEVA sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de TEVA | |
|---|---|
| Ingresos | US$16.29b |
| Coste de los ingresos | US$8.23b |
| Beneficio bruto | US$8.06b |
| Otros gastos | US$8.52b |
| Beneficios | -US$453.00m |
Últimos beneficios comunicados
Jun 30, 2024
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.40 |
| Margen bruto | 49.50% |
| Margen de beneficio neto | -2.78% |
| Ratio deuda/patrimonio | 284.0% |
¿Cómo se ha desempeñado TEVA a largo plazo?
Ver rendimiento histórico y comparativa